NEOGENOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.14 USD | +2.09% |
|
+4.51% | -12.61% |
| 18/04 | NeoGenomics, Inc. Announces Senior Leadership Promotions | CI |
| 18/04 | NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics | CI |
| Sales 2024 * | 655M 54.59B | Sales 2025 * | 719M 59.94B | Capitalization | 1.81B 151B |
|---|---|---|---|---|---|
| Net income 2024 * | -71M -5.92B | Net income 2025 * | -51M -4.25B | EV / Sales 2024 * | 3.19 x |
| Net Debt 2024 * | 286M 23.88B | Net Debt 2025 * | 272M 22.65B | EV / Sales 2025 * | 2.89 x |
| P/E ratio 2024 * |
-25.1
x | P/E ratio 2025 * |
-35.8
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on NeoGenomics, Inc.
More recommendations
More press releases
| 1 day | +2.09% | ||
| 1 week | +4.51% | ||
| Current month | -10.05% | ||
| 1 month | -6.73% | ||
| 3 months | -9.42% | ||
| 6 months | -2.55% | ||
| Current year | -12.61% |
1 week
13.34
14.47
1 month
13.3415.91
Current year
13.3417.49
1 year
11.0321.22
3 years
6.0054.74
5 years
6.0061.57
10 years
2.9861.57
| Managers | Title | Age | Since |
|---|---|---|---|
Chris Smith
CEO | Chief Executive Officer | 61 | 15/22/15 |
Lynn Tetrault
CHM | Chairman | 61 | 12/15/12 |
Jeffrey Sherman
DFI | Director of Finance/CFO | 58 | 07/22/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Crowther
BRD | Director/Board Member | 72 | 22/14/22 |
Michael Kelly
BRD | Director/Board Member | 67 | 15/20/15 |
Chris Smith
CEO | Chief Executive Officer | 61 | 15/22/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.43% | 16 M€ | -8.49% | ||
| 0.97% | 11 M€ | -6.03% | - | |
| 0.29% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.14 | +2.09% | 830,782 |
| 25/24/25 | 13.85 | -1.28% | 792,553 |
| 24/24/24 | 14.03 | -0.92% | 539,066 |
| 23/24/23 | 14.16 | +5.51% | 853,984 |
| 22/24/22 | 13.42 | -0.81% | 801,907 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Calendar
30/04/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.14
USD
Average target price
21.1
USD
Spread / Average Target
+49.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.61% | 1.81B | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- NEO Stock
